$63.99
0.05% day before yesterday
Nasdaq, Jul 18, 10:00 pm CET
ISIN
US4364401012
Symbol
HOLX

Hologic Stock price

$63.99
+0.02 0.03% 1M
-5.74 8.23% 6M
-8.10 11.24% YTD
-13.67 17.60% 1Y
-4.48 6.54% 3Y
+2.56 4.17% 5Y
+26.09 68.84% 10Y
+54.49 573.58% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
-0.03 0.05%
ISIN
US4364401012
Symbol
HOLX
Sector

Key metrics

Basic
Market capitalization
$14.3b
Enterprise Value
$15.2b
Net debt
$910.0m
Cash
$1.6b
Shares outstanding
222.8m
Valuation (TTM | estimate)
P/E
26.0 | 15.0
P/S
3.5 | 3.4
EV/Sales
3.8 | 3.7
EV/FCF
15.6
P/B
3.1
Financial Health
Equity Ratio
56.0%
Return on Equity
15.4%
ROCE
13.0%
ROIC
12.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$4.0b | $4.2b
EBITDA
$1.0b | $1.4b
EBIT
$983.7m | $1.2b
Net Income
$556.7m | $950.5m
Free Cash Flow
$970.1m
Growth (TTM | estimate)
Revenue
1.7% | 3.0%
EBITDA
9.1% | 35.8%
EBIT
11.0% | 26.9%
Net Income
19.3% | 20.4%
Free Cash Flow
2.2%
Margin (TTM | estimate)
Gross
56.4%
EBITDA
24.9% | 32.7%
EBIT
24.4%
Net
13.8% | 22.9%
Free Cash Flow
24.1%
More
EPS
$2.5
FCF per Share
$4.4
Short interest
3.0%
Employees
7k
Rev per Employee
$570.0k
Show more

Is Hologic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Hologic Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Hologic forecast:

11x Buy
39%
16x Hold
57%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Hologic forecast:

Buy
39%
Hold
57%
Sell
4%

Financial data from Hologic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,027 4,027
2% 2%
100%
- Direct Costs 1,754 1,754
1% 1%
44%
2,273 2,273
4% 4%
56%
- Selling and Administrative Expenses 1,021 1,021
4% 4%
25%
- Research and Development Expense 249 249
13% 13%
6%
1,002 1,002
9% 9%
25%
- Depreciation and Amortization 19 19
42% 42%
0%
EBIT (Operating Income) EBIT 984 984
11% 11%
24%
Net Profit 557 557
19% 19%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Hologic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hologic Stock News

Neutral
Business Wire
18 days ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025.
Neutral
Business Wire
about 2 months ago
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.
Neutral
Proactive Investors
about 2 months ago
TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a media report from the Financial Times. Citing people with knowledge of the matter, the publication said Massachusetts-based Hologic has rejected the offer.
More Hologic News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.

Head office United States
CEO Stephen MacMillan
Employees 7,063
Founded 1985
Website www.hologic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today